Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ICLR Stock Forecast 2026-2027
$115.18
Current Price
$9.11B
Market Cap
Buy 8
Hold 6
Sell 1
Wall St Analyst Ratings
Distance to ICLR Price Targets
+56.3%
To High Target of $180.00
+12.9%
To Median Target of $130.00
-34.9%
To Low Target of $75.00
ICLR Price Momentum
-1.1%
1 Week Change
+15.5%
1 Month Change
-15.8%
1 Year Change
-36.8%
Year-to-Date Change
-45.4%
From 52W High of $211.00
+73.0%
From 52W Low of $66.57
📊 TOP ANALYST CALLS
Did ICLR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ICON is one of their latest high-conviction picks.
Latest ICLR Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, ICLR has a bullish consensus with a median price target of $130.00 (ranging from $75.00 to $180.00). The overall analyst rating is Buy (7.9/10). Currently trading at $115.18, the median forecast implies a 12.9% upside. This outlook is supported by 8 Buy, 6 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Luke Sergott at Barclays, projecting a 56.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICLR Analyst Ratings
8
Buy
6
Hold
1
Sell
ICLR Price Target Range
Low
$75.00
Average
$130.00
High
$180.00
Current: $115.18
Latest ICLR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICLR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 26, 2026 | BMO Capital | Sean Dodge | Outperform | Upgrade | $130.00 |
| Mar 11, 2026 | Citigroup | Patrick Donnelly | Neutral | Maintains | $120.00 |
| Mar 9, 2026 | Barclays | Luke Sergott | Equal-Weight | Maintains | $120.00 |
| Feb 23, 2026 | Jefferies | David Windley | Buy | Upgrade | $135.00 |
| Feb 18, 2026 | TD Cowen | Charles Rhyee | Buy | Upgrade | $120.00 |
| Jan 22, 2026 | TD Cowen | Charles Rhyee | Hold | Maintains | $183.00 |
| Jan 8, 2026 | Truist Securities | Jailendra Singh | Hold | Downgrade | $222.00 |
| Dec 15, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $200.00 |
| Nov 13, 2025 | BMO Capital | Sean Dodge | Market Perform | Initiates | $175.00 |
| Oct 24, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $185.00 |
| Oct 24, 2025 | TD Cowen | Charles Rhyee | Hold | Maintains | $172.00 |
| Oct 2, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $190.00 |
| Sep 9, 2025 | Jefferies | David Windley | Hold | Downgrade | $175.00 |
| Sep 3, 2025 | Rothschild & Co | Jamie Clark | Buy | Upgrade | $236.00 |
| Sep 2, 2025 | Baird | Eric Coldwell | Outperform | Maintains | $224.00 |
| Aug 21, 2025 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $200.00 |
| Jul 25, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $180.00 |
| Jul 25, 2025 | UBS | John Sourbeer | Buy | Maintains | $240.00 |
| Jul 25, 2025 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $240.00 |
| Jul 25, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $225.00 |
ICON plc (ICLR) Competitors
The following stocks are similar to ICON based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ICON plc (ICLR) Financial Data
ICON plc has a market capitalization of $9.11B with a P/E ratio of 16.1x. The company generates $8.10B in trailing twelve-month revenue with a 7.4% profit margin.
Revenue growth is +0.6% quarter-over-quarter, while maintaining an operating margin of +12.7% and return on equity of +6.3%.
Valuation Metrics
Market Cap
$9.11B
Enterprise Value
$12.24B
P/E Ratio
16.1x
PEG Ratio
-0.2x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
+0.6%
Gross Margin
+27.1%
Operating Margin
+12.7%
Net Margin
+7.4%
EPS Growth
-98.8%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
1.1x
Debt/Equity
38.3x
ROE
+6.3%
ROA
+4.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ICON plc (ICLR) Business Model
About ICON plc
What They Do
Provides outsourced drug and device development services.
Business Model
ICON plc operates as a contract research organization (CRO), earning revenue by offering comprehensive clinical trial services, from initial research phases to commercialization. The company partners with pharmaceutical and biotechnology clients, providing tailored solutions including project management, data management, and advanced technology integration to enhance trial efficiency and reduce costs.
Additional Information
Founded in 1990 and based in Dublin, Ireland, ICON plc has a strong global presence, enabling it to support a wide range of therapeutic areas and product life cycles. The company emphasizes innovation through AI and data analytics, optimizing trial processes and improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
39,900
CEO
Dr. Steven A. Cutler MBA, Ph.D.
Country
Ireland
IPO Year
1998
Website
www.iconplc.comICON plc (ICLR) Latest News & Analysis
Latest News
Quick Summary
In Q1, Artisan Mid Cap Value Fund underperformed the Russell Midcap® Value Index, impacted by momentum-driven stocks. Major decliners included ICON, Gartner, and Pinterest. New significant buys were Brown & Brown, Veralto, and IQVIA Holdings.
Why It Matters
The Artisan Mid Cap Value Fund's underperformance highlights challenges in a momentum-driven market, affecting investor confidence. Major declines in key holdings signal potential volatility and risk.
Source: Seeking Alpha
Market Sentiment:
Negative
Quick Summary
ICON plc and Advarra have formed a partnership to launch a 'research-ready' connected site network for clinical trials, integrating ICON’s solutions with Advarra's technology platforms.
Why It Matters
The partnership between ICON plc and Advarra enhances clinical trial efficiency, potentially leading to faster drug approvals and increased revenues, positively impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lowey Dannenberg P.C. is investigating ICON PLC (NASDAQ: ICLR) for possible violations of federal securities laws, which may impact investors.
Why It Matters
The investigation into ICON PLC for potential securities law violations could lead to legal ramifications, impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ICLR ALERT: Ongoing Investigation Into ICON Public Limited Company - Contact Levi & Korsinsky
1 month ago
Quick Summary
Levi & Korsinsky is investigating ICON Public Limited Company (NASDAQ: ICLR) for potential federal securities law violations after a significant single-day stock decline affecting shareholder value.
Why It Matters
The investigation into ICON Public Limited Company suggests potential legal issues, raising concerns about compliance and financial stability, which can significantly impact investor confidence and stock value.
Source: Newsfile Corp
Market Sentiment:
Neutral
Lost Money on ICON Public Limited Company (ICLR)? Possible Fraud - Contact Levi & Korsinsky Today
1 month ago
Quick Summary
Levi & Korsinsky is investigating ICON Public Limited Company (NASDAQ: ICLR) for potential federal securities law violations after a significant decline affected shareholder value.
Why It Matters
The investigation into ICON Public Limited Company over potential federal securities law violations could indicate serious financial risks, impacting share prices and investor confidence significantly.
Source: Newsfile Corp
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ICON plc – ICLR
1 month ago
Quick Summary
Pomerantz LLP is investigating claims for ICON plc (NASDAQ: ICLR) investors. Interested parties should contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Why It Matters
The investigation into ICON plc may indicate potential legal issues, which could impact the company's stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ICLR Stock
What is ICON plc's (ICLR) stock forecast for 2026?
Based on our analysis of 31 Wall Street analysts, ICON plc (ICLR) has a median price target of $130.00. The highest price target is $180.00 and the lowest is $75.00.
Is ICLR stock a good investment in 2026?
According to current analyst ratings, ICLR has 8 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $115.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICLR stock?
Wall Street analysts predict ICLR stock could reach $130.00 in the next 12 months. This represents a 12.9% increase from the current price of $115.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ICON plc's business model?
ICON plc operates as a contract research organization (CRO), earning revenue by offering comprehensive clinical trial services, from initial research phases to commercialization. The company partners with pharmaceutical and biotechnology clients, providing tailored solutions including project management, data management, and advanced technology integration to enhance trial efficiency and reduce costs.
What is the highest forecasted price for ICLR ICON plc?
The highest price target for ICLR is $180.00 from Luke Sergott at Barclays, which represents a 56.3% increase from the current price of $115.18.
What is the lowest forecasted price for ICLR ICON plc?
The lowest price target for ICLR is $75.00 from at , which represents a -34.9% decrease from the current price of $115.18.
What is the overall ICLR consensus from analysts for ICON plc?
The overall analyst consensus for ICLR is bullish. Out of 31 Wall Street analysts, 8 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $130.00.
How accurate are ICLR stock price projections?
Stock price projections, including those for ICON plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:01 AM UTC